TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma

被引:88
|
作者
Albert, Nathalie L. [1 ,2 ,3 ,4 ]
Unterrainer, M. [1 ]
Fleischmann, D. F. [2 ,3 ,5 ]
Lindner, S. [1 ]
Vettermann, F. [1 ]
Brunegraf, A. [1 ]
Vomacka, L. [1 ]
Brendel, M. [1 ]
Wenter, V. [1 ]
Wetzel, C. [6 ]
Rupprecht, R. [6 ]
Tonn, J. -C. [2 ,3 ,7 ]
Belka, C. [2 ,3 ,5 ]
Bartenstein, P. [1 ,2 ,3 ,4 ]
Niyazi, M. [2 ,3 ,5 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Nucl Med, Marchioninistr 15, D-81377 Munich, Germany
[2] German Canc Consortium DKTK, Partner Site Munich, Heidelberg, Germany
[3] German Canc Res Ctr, Heidelberg, Germany
[4] Bunich Cluster Syst Neurol SyNergy, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany
[6] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany
[7] Ludwig Maximilians Univ Munchen, Dept Neurosurg, Munich, Germany
关键词
Glioma; F-18-GE-180; TSPOPET; Radiotherapy planning; POSITRON-EMISSION-TOMOGRAPHY; BENZODIAZEPINE-BINDING-SITES; TRANSLOCATOR PROTEIN; F-18-FET PET; MICROGLIAL ACTIVATION; EXPRESSION; BRAIN; DIAGNOSIS; TRACER; GRADE;
D O I
10.1007/s00259-017-3799-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective The 18-kDa mitochondrial translocator protein (TSPO) was reported to be upregulated in gliomas. F-18-GE-180 is a novel 3rd generation TSPO receptor ligand with improved target-to-background contrast compared to previous tracers. In this pilot study, we compared PET imaging with F-18-GE-180 and MRI of patients with untreated and recurrent pretreated glioblastoma. Methods Eleven patients with histologically confirmed IDH wildtype gliomas (10 glioblastomas, 1 anaplastic astrocytoma) underwent F-18-GE-180 PET at initial diagnosis or recurrence. The PET parameters mean background uptake (SUVBG), maximal tumour-to-background ratio (TBRmax) and PET volume using different thresholds (SUVBG x 1.6, 1.8 and 2.0) were evaluated in the 60-80 min p.i. summation images. The different PET volumes were compared to the contrast-enhancing tumour volume on MRI. Results All gliomas were positive on F-18-GE-180 PET and were depicted with extraordinarily high tumour-to-background contrast (median SUVBG 0.47 (0.37-0.93), TBRmax 6.61 (3.88-9.07)). F-18-GE-180 uptake could be found even in areas without contrast enhancement on MRI, leading to significantly larger PET volumes than MRI-based volumes (median 90.5, 74.5, and 63.8 mL vs. 31.0 mL; p = 0.003, 0.004, 0.013). In percentage difference, the PET volumes were on average 179%, 135%, and 90% larger than the respective MRI volumes. The median spatial volumetric correlation (Sorensen-Dice coefficient) of PET volumes and MRI volumes prior to radiotherapy was 0.48, 0.54, and 0.58. Conclusion F-18-GE-180 PET provides a remarkably high tumour-to-background contrast in untreated and pretreated glioblastoma and shows tracer uptake even beyond contrast enhancement on MRI. To what extent F-18-GE-180 uptake reflects the tumour extent of human gliomas and inflammatory cells remains to be evaluated in future prospective studies with guided stereotactic biopsies and correlation of histopathological results.
引用
收藏
页码:2230 / 2238
页数:9
相关论文
共 50 条
  • [1] TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma
    Nathalie L. Albert
    M. Unterrainer
    D. F. Fleischmann
    S. Lindner
    F. Vettermann
    A. Brunegraf
    L. Vomacka
    M. Brendel
    V. Wenter
    C. Wetzel
    R. Rupprecht
    J.-C. Tonn
    C. Belka
    P. Bartenstein
    M. Niyazi
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 2230 - 2238
  • [2] TSPO PET using 18F-GE-180: a new perspective in neurooncology?
    Langen, Karl-Josef
    Willuweit, Antje
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (13) : 2227 - 2229
  • [3] TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
    Unterrainer, M.
    Fleischmann, D. F.
    Vettermann, F.
    Ruf, V
    Kaiser, L.
    Nelwan, D.
    Lindner, S.
    Brendel, M.
    Wenter, V
    Stoecklein, S.
    Herms, J.
    Milenkovic, V. M.
    Rupprecht, R.
    Tonn, J. C.
    Belka, C.
    Bartenstein, P.
    Niyazi, M.
    Albert, N. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (06) : 1368 - 1380
  • [4] Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180
    Unterrainer, Marcus
    Fleischmann, Daniel F.
    Lindner, Simon
    Brendel, Matthias
    Rupprecht, Rainer
    Tonn, Joerg C.
    Belka, Claus
    Bartenstein, Peter
    Niyazi, Maximilian
    Albert, Nathalie L.
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (07) : 518 - 519
  • [5] TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis
    Vomacka, Lena
    Albert, Nathalie Lisa
    Lindner, Simon
    Unterrainer, Marcus
    Mahler, Christoph
    Brendel, Matthias
    Ermoschkin, Larissa
    Gosewisch, Astrid
    Brunegraf, Anika
    Buckley, Christopher
    Kuempfel, Tania
    Rupprecht, Rainer
    Ziegler, Sibylle
    Kerschensteiner, Martin
    Bartenstein, Peter
    Boening, Guido
    EJNMMI RESEARCH, 2017, 7
  • [6] Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI
    De Groot, Marius
    Patel, Neel
    Manavaki, Roido
    Janiczek, Robert L.
    Bergstrom, Mats
    Ostor, Andrew
    Gerlag, Danielle
    Roberts, Alexandra
    Graves, Martin J.
    Karkera, Yakshitha
    Fernando, Disala
    Mistry, Prafull
    Walker, Adam
    Wisniacki, Nicolas
    Fryer, Tim D.
    Jimenez-Royo, Pilar
    EJNMMI RESEARCH, 2019, 9 (01)
  • [7] TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
    M. Unterrainer
    D. F. Fleischmann
    F. Vettermann
    V. Ruf
    L. Kaiser
    D. Nelwan
    S. Lindner
    M. Brendel
    V. Wenter
    S. Stöcklein
    J. Herms
    V. M. Milenkovic
    R. Rupprecht
    J. C. Tonn
    C. Belka
    P. Bartenstein
    M. Niyazi
    N. L. Albert
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 1368 - 1380
  • [8] Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study
    Unterrainer, Marcus
    Fleischmann, D. F.
    Diekmann, C.
    Vomacka, L.
    Lindner, S.
    Vettermann, F.
    Brendel, M.
    Wenter, V.
    Ertl-Wagner, B.
    Herms, J.
    Wetzel, C.
    Rupprecht, R.
    Tonn, J. C.
    Belka, C.
    Bartenstein, P.
    Niyazi, M.
    Albert, Nathalie L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 580 - 590
  • [9] TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas
    Quach, Stefanie
    Holzgreve, Adrien
    Kaiser, Lena
    Unterrainer, Marcus
    Dekorsy, Franziska J.
    Nelwan, Debie, V
    Bartos, Laura M.
    Kirchleitner, Sabrina, V
    Weller, Jonathan
    Weidner, Lorraine
    Niyazi, Maximilian
    Ruf, Viktoria C.
    Herms, Jochen
    Stoecklein, Sophia
    Wetzel, Christian
    Riemenschneider, Markus J.
    Baumgarten, Louisa, V
    Thon, Niklas
    Brendel, Matthias
    Rupprecht, Rainer
    Bartenstein, Peter
    Tonn, Joerg-Christian
    Albert, Nathalie L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (03) : 859 - 869
  • [10] Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET
    Vettermann, Franziska J.
    Unterrainer, Marcus
    Ruf, Viktoria
    Fleischmann, Daniel F.
    Rupprecht, Rainer
    Forbrig, Robert
    Herms, Jochen
    Tonn, Joerg C.
    Belka, Claus
    Bartenstein, Peter
    Niyazi, Maximilian
    Albert, Nathalie L.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : 992 - 993